Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO 42 EV-to-OCF is 0.52 as of Sep. 11, 2026, which is 225% above its 10-year median of 0.16. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,405 Biotechnology companies, SILO Pharma ranks worse than 76.37% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, SILO Pharma's Enterprise Value is $-1.75 Mil.
SILO Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.34 Mil. Therefore, SILO Pharma's EV-to-OCF for today is 0.52.
The historical rank and industry rank for SILO Pharma's EV-to-OCF or its related term are showing as below:
SILO'
s EV-to-OCF Range Over the Past 10 Years
Min: -9642.38 Med: 0.16 Max: 181.51
Current: 0.52
During the past 13 years, the highest EV-to-OCF of SILO Pharma was 181.51. The lowest was -9642.38. And the median was 0.16.
SILO's EV-to-OCF is ranked worse than 76.37% of 1405
companies
in the Biotechnology industry
Industry Median: -3.4
vs SILO: 0.52
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SILO Pharma's PE Ratio (TTM) for today is calculated as:
SILO Pharma's share price for today is $2.10.
SILO Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.353.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SILO Pharma EV-to-OCF Related Terms
SILO Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for SILO Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SILO Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where SILO Pharma's EV-to-OCF falls into.
SILO Pharma's current Enterprise Value is $-1.75 Mil.
SILO Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (SILO) has a EV-to-OCF of 0.52 as of Sep. 11, 2026. This is 225% above median its historical median of 0.16. According to the industry distribution chart, SILO Pharma ranks #1073 out of 1405 companies in the Biotechnology industry, placing it in the top 76.4%.
Is SILO Pharma's EV-to-OCF too high?
SILO Pharma's current EV-to-OCF of 0.52 is 225% above median its 10-year median of 0.16. Based on the distribution chart, SILO Pharma ranks #1073 out of 1405 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's EV-to-OCF compare to ELAB and GLMD?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #1073 out of 1405 companies for EV-to-OCF. This places SILO Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. SILO Pharma's current EV-to-OCF is 0.52, which is 225% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current EV-to-OCF is 0.52, which is 225% above median its 10-year median of 0.16. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For SILO Pharma (SILO), the current EV-to-OCF is 0.52 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44.
GuruFocus considers SILO Pharma to be Possible Value Trap.
Key valuation signals for SILO:
EV-to-OCF: 0.52 (225% above median its 10-year median of 0.16)
GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score
Get the complete analysis for SILO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
